Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator

Adeona Pharmaceuticals, Inc. AEN announced today that the Company's clinical collaborator for amyotrophic lateral sclerosis, PNA Center for Neurological Research, reported top-line results from its pilot Phase I/II open label, three month safety study of oral high dose zinc therapy in ALS, also known as Lou Gehrig's disease. The clinical study met its primary outcome as no safety issues related to zinc therapy were observed. In addition, an average decrease in the monthly rate of disease progression was observed in the ALS patients on zinc therapy, compared to published historical controls, as well as compared to the average monthly rate of disease progression of the subjects prior to enrollment in the study.